Hannah Edwards, MD
Internal Medicine · Chattanooga, TNNPI 1235793449
Payments from drug & device makers
Across 167 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$456
- Pfizer$336
- Amgen$323
- AstraZeneca$262
- AbbVie$247
- Lilly USA, LLC$228
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,94699%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $456 |
| Pfizer | 22 | $336 |
| Amgen | 24 | $323 |
| AstraZeneca | 12 | $262 |
| AbbVie | 14 | $247 |
| Lilly USA, LLC | 13 | $228 |
| Boehringer Ingelheim | 8 | $139 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $110 |
| Astellas Pharma US Inc | 3 | $93 |
| Sumitomo Pharma America, Inc. | 4 | $75 |
| GSK | 5 | $75 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Exact Sciences | 3 | $46 |
| Abbott | 2 | $44 |
| Novartis | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Medtronic | 1 | $37 |
| Merck | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Currax Pharmaceuticals LLC | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Corium, LLC | 1 | $24 |
| Nevro Corp. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Cequr Corporation | 1 | $20 |
| Seqirus USA Inc | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Bayer | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
How this compares
$2,971 in reported general payments places this provider in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 175 | $189,537 |
| OzempicSemaglutide | 96 | $109,494 |
| JardianceEmpagliflozin | 107 | $102,808 |
| FarxigaDapagliflozin Propanediol | 97 | $95,222 |
| EliquisApixaban | 99 | $89,627 |
| RybelsusSemaglutide | 14 | $32,601 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $26,695 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $26,181 |
| Nurtec OdtRimegepant Sulfate | 13 | $24,574 |
| XareltoRivaroxaban | 37 | $23,698 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $17,694 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $16,819 |
| TrulicityDulaglutide | 15 | $15,440 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $10,871 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $228 | $204,977190 claims |
| Novo NordiskOzempic, Rybelsus | $456 | $142,095110 claims |
| PfizerEliquis, Nurtec Odt | $336 | $114,201112 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $139 | $108,382118 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $262 | $103,540111 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $75 | $33,65149 claims |
| MerckJanumet Xr | $34 | $3,21612 claims |
| AbbVieSynthroid | $247 | $3,18047 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Chattanooga
- Mark McKenzieChattanooga$11.9M
- Charles CrumpChattanooga$1M
- Eugene RyanChattanooga$636K
- Valerie BoazChattanooga$105K
- Carlton VollbergChattanooga$105K
- Maighan SeagroveChattanooga$78K
- Jeremy HogstromChattanooga$30K
- Jermaine HogstromChattanooga$29K
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.